Comparison of the Administration of Nobelgin and Novafen in Pain Control After Implant

Comparison of the Administration of Nobelgin and Novafen in Pain Control After Dental Implants Surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240927063186N1

Enrollment

Registered

2024-10-23

Start date

2024-08-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental implant surgery.

Interventions

Intervention 1: Intervention group: receiving Novafen, (CombinationTablet Includes: 325 mg Acetaminophen, 200 mg Ibuprofen and 40 mg Caffeine) (Iran Daroo, Tehran, Iran), one capsule every 6 hours for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age range above 18 years to 40 years Sufficient alveolar bone thickness of at least 6.5 mm in the area to be implanted Clients with ASA 1 or 2 No need for bone graft(GBR)

Exclusion criteria

Exclusion criteria: History of allergy to NSAIDs Referral of the patient to the office with active bleeding Tooth decay in the vicinity of the surgery site History of housing consumption in the last 24 hours Mental disorders and severe pain reactions Elderly and people with osteodegenerative diseases such as uncontrolled diabetes and rheumatoid arthritis People who consume bisphosphonates People who drink alcohol

Design outcomes

Primary

Measure	Time frame
Pain intensity using the Verbal Rating Scale (VRS). Timepoint: at 1, 12, 24, 48 and 72 hours after surgery. Method of measurement: Verbal Rating Scale (VRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Mirzaei

Oroumia University of Medical Sciences

Z.mirzaei.8310@gmail.com+98 44 3224 2564

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026